| Issue Date |
Title |
Author(s) |
| Jun-2020 |
Comparison of the Efficacy and Safety of Adalimumab (Humira) and the Adalimumab Biosimilar Candidate (HS016) in Chinese Patients with Active Ankylosing Spondylitis: A Multicenter, Randomized, Double-Blind, Parallel, Phase III Clinical Trial |
Su, Jinmei;Li, Mengtao;He, Lan;Zhao, Dongbao;Wan, Weiguo;Liu, Yi;Xu, Jianhua;Xu, Jian;Liu, Huaxiang;Jiang, Lindi;Wu, Huaxiang;Zuo, Xiaoxia;Huang, Cibo;Liu, Xiumei;Li, Fen;Zhang, Zhiyi;Liu, Xiangyuan;Dong, Lingli;Li, Tianwang;Chen, Haiying;Li, Jingyang;He, Dongyi;Lu, Xin;Huang, Anbin;Tao, Yi;Wang, Yanyan;Zhang, Zhuoli;Wei, Wei;Li, Xiaofeng;Zeng, Xiaofeng |
| Sep-2020 |
Development and formulation of the classification criteria for osteoarthritis |
Huang, Cibo;Zhang, Zhiyi;Chen, Yaolong;Zhang, Yue;Xing, Dan;Zhao, Like;Lin, Jianhao;Mei, Yifang;Lin, Hsiao-Yi;Zheng, Yi;Tsai, Wei-Chung;Liu, Shengyun;Jiang, Quan;Liu, Yi;Chen, Jinwei;Ye, Zhizhong;Chen, Min;Chen, Yingjuan;Chu, Cong-Qiu;Gao, Ming;He, Lan;Lin, Jin;Wu, Lijun;Xu, Jianhua;Yang, Pinting;Zhang, Xuewu;Jiang, Qing;Lei, Guanghua;Li, Mengtao;Yang, Wanling;Gu, Xin;Zhou, Yixin;He, Dongyi;Liu, Wei;Zhang, Weiya;Ding, Changhai;Zeng, Xiaofeng |
| 2016 |
Dietary intake and risk of rheumatoid arthritis-a cross section multicenter study |
He, Jing;Wang, Yu;Feng, Min;Zhang, Xia;Jin, Yue-Bo;Li, Xue;Su, Lin-Chong;Liu, Shuang;Wang, Ai-Xue;Chen, Xiao-Mei;Wu, Li-Jun;Yu, Xiao-Xia;Xu, Ning;Liu, Xiang-Yuan;Yan, Hui-Ming;Wang, Yong-Fu;Jia, Bin;Li, Jun-Fang;Tao, Jie-Mei;Zhang, Feng-Xiao;Yu, Ping;Cui, Liu-Fu;Yang, Jing;Li, Zhen-Bin;Xie, Jian-Li;Wei, Ping;Sun, Wen-Wen;Gong, Lu;Cheng, Yong-Jing;Huang, Ci-Bo;Wang, Xiao-Yuan;Wang, Yi;Guo, Hui-Fang;Jin, Hong-Tao;Liu, Xia;Wang, Guo-Chun;Wang, Yan-Hua;He, Lan;Zhao, Yi;Li, Xiao-Xia;Zhang, Yan;Guo, Jian-Ping;Li, |
| Oct-2020 |
Guidelines for the diagnosis and treatment of osteoarthritis in China (2019 edition) |
Zhang, Zhiyi;Huang, Cibo;Jiang, Quan;Zheng, Yi;Liu, Yi;Liu, Shengyun;Chen, Yingjuan;Mei, Yifang;Ding, Changhai;Chen, Min;Gu, Xin;Xing, Dan;Gao, Min;He, Lan;Ye, Zhizhong;Wu, Lijun;Xu, Jianhua;Yang, Pinting;Zhang, Xuewu;Zhang, Yue;Chen, Jinwei;Lin, Jin;Zhao, Like;Li, Mengtao;Yang, Wanling;Zhou, Yixin;Jiang, Qing;Chu, Cong-Qiu;Chen, Yaolong;Zhang, Weiya;Tsai, Wei-Chung;Lei, Guanghua;He, Dongyi;Liu, Wei;Fang, Yongfei;Wu, Darong;Lin, Jianhao;Wei, Cheng-Chung;Lin, Hsiao-Yi;Zeng, Xiaofeng |
| 2019 |
A MULTICENTRE, RANDOMISED, DOUBLE-BLIND, PARALLEL ACTIVE-CONTROLLED CLINICAL TRIAL COMPARING PHARMACOKINETICS, PHARMACODYNAMICS, SAFETY AND EXPLORATORY EFFICACY BETWEEN HLX01 AND EUROPE-SOURCED RITUXIMAB AS A NEW INDICATION IN CHINESE MODERATE TO SEVERE PA |
Zeng, Xiaofeng;Wang, Yongfu;Jiang, Zhenyu;Zhang, Zhuoli;He, Lan;Zhang, Xiao;Lu, Xin;Liu, Xiumei;Xu, Jian;Huang, Cibo;Liu, Rui;Zuo, Xiaoxia;Zhao, Baozeng;Qiu, Wenting;Chai, Katherine;Guo, Xinjun;Zhang, Xin;Liu, Eugene;Luk, Alvin;Jiang, Weidong;Liu, Scott;Hu, Pei;Chen, Xia |
| 2017 |
Rapid Onset of Response Observed with Certolizumab Pegol in Rheumatoid Arthritis Patients with Inadequate Response to Methotrexate: Efficacy and Safety Results of a Randomized, Double-Blind, Placebo-Controlled Phase 3 Study |
Bi, Liqi;Li, Yuhui;He, Lan;Xu, Huji;Gu, Jieruo;Wang, Guochun;Zhang, Zhiyi;Liu, Yi;Boehnlein, Marion;Dunkel, Jochen;Shao, Jing;Harris, Kristina;Li, Zhanguo |
| 2015 |
TRIM30 alpha Is a Negative-Feedback Regulator of the Intracellular DNA and DNA Virus-Triggered Response by Targeting STING |
Wang, Yanming;Lian, Qiaoshi;Yang, Bo;Yan, Shanshan;Zhou, Haiyan;He, Lan;Lin, Guomei;Lian, Zhexiong;Jiang, Zhengfan;Sun, Bing |
| 2017 |
The usage of biological DMARDs and clinical remission of rheumatoid arthritis in China: a real-world large scale study |
An, Yuan;Liu, Tian;He, Dongyi;Wu, Lijun;Li, Juan;Liu, Yi;Bi, Liqi;Zhou, Bin;Lin, Changsong;He, Lan;Liu, Xiangyuan;Li, Xiaofeng;Yang, Niansheng;Zhang, Zhuoli;Song, Hui;Wei, Wei;Liu, Jing;Bi, Yu;Li, Zhanguo |
